Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories is positioned to experience continuous growth in the animal health diagnostics and services industry, leveraging their global leadership in the sector. With a strong commercial organization and a diverse and synergistic product portfolio, including innovative new tests and software services, the company is well-positioned for future success. Despite facing some headwinds, such as competition and current macroeconomic pressures, IDXX has shown strong financial performance, indicating its ability to adapt and thrive in challenging circumstances. As such, the analyst maintains a positive outlook on the company's stock.

Bears say

IDEXX Laboratories is viewed negatively by analysts due to a combination of industry headwinds, including staffing shortages and inflation, that have resulted in slower growth for the animal health industry. While IDEXX has been able to outpace sector growth due to its strong value proposition, customer engagement, and unique solutions, there is a risk that the company's stock valuation may pull back and trade more in line with other diagnostics or medical technology companies. Additionally, the recent CEO transition from Jay Mazelsky to Mike Erickson may cause some uncertainty and could potentially impact the company's performance in the short term.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $721.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $721.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.